Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of H008-based bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2200058521Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of keverprazan and esomeprazole in Helicobacter pylori infection (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Hp eradication rate after 4 weeks. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
keverprazanesomeprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200058521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058521.